Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Jun 11, 2024 8:06pm
177 Views
Post# 36083807

RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs

RE:RE:RE:RE:Inflation Reduction Act (IRA) boosts biological drugs Nice capulation of the upcoming & changing trends in cancer care.
Oncolytics biotech, fit into 4 of the 4, categories.
Yes Onc has been around 20+ years.
however the technology & science to support the co- therapeutic use, is certainly on the upswing.
Utilizing & understanding the 4 points 
Targeted therapy, precision medicine, oncokytics viruses, liquid biopsies.
All in some form related to ONCs Pelareorep.
There is a lot more " value" than then known.
upcoming pancreatic cancer co- therapy with Roche.
mbc cancer therapy 
The CAR-t , studies are still in the background.
Not discussed, but the immunotherapy opportunities are yet to be explored.
They have seen inate adaptation of Pelareorep affects on the imune system.
AkA, cancer vaccination.
Long way out, but not impossible.
It has long been known that everyone has cancer cells in our body at all times.
majority of the time the imune system fights it off.
enough of that.

<< Previous
Bullboard Posts
Next >>